Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Odyssey Group Intl Inc (OP: ODYY )

0.0175 UNCHANGED
Streaming Delayed Price Updated: 2:08 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Odyssey Group Intl Inc

< Previous 1 2 3 Next >
Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Helmets Will Not Protect Individuals Against Concussions, Expert Says
Via Investor Brand Network
New Study Finds Hypertension Accelerates Bone Aging
Via Investor Brand Network
Ways to Prevent a Child from Choking
Via Investor Brand Network
Research to Examine Potential Link Between Concussions, Long COVID
Via Investor Brand Network
Exposures COVID-19
Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002
Via Investor Brand Network
Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs
Via Investor Brand Network
NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial
Via Investor Brand Network
Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product
Via Investor Brand Network
Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Via Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview
Via Investor Brand Network
Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy
Via Investor Brand Network
Topics Animal Testing
Exposures Animal Testing
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.